To the Editor We read with great interest the study by Reyes-Hadsall et al1 on the use of shared decision-making (SDM) and decisional regret in patients with alopecia areata (AA). Dermatology therapeutics is rapidly evolving, with many associated uncertainties. As a result, our task as clinicians to help navigate patients through treatment options and risk/benefit perception has become more challenging. Internationally, SDM is considered core to good clinical practice. The UK National Institute of Health and Care Excellence has created SDM guidelines covering how to make SDM part of everyday care in health care settings and promotes its inclusion in organizational culture and practices.2